BID | 58.89 | ASK | 62.68 | ||
Open | 59.82 | Previous Close | 60.66 | ||
Pre-Market | - | After-Market | 60.80 | ||
- - | - -% |
Target Price | 100.40 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 65.13 | Finscreener Ranking | ★★★★+ 54.98 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 50.67 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 72.29 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 56.97 | Earnings Rating | Strong Buy | |
Market Cap | 4.18B | Earnings Date | 23rd Feb 2023 | |
Alpha | 0.03 | Standard Deviation | 0.17 | |
Beta | 0.75 |
Today's Price Range 59.7660.93 | 52W Range 25.4987.47 | 5 Year PE Ratio Range -56.6029.40 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 8.19% | ||
1 Month | 19.17% | ||
3 Months | 0.33% | ||
6 Months | -14.65% | ||
1 Year | 132.24% | ||
3 Years | 247.03% | ||
5 Years | 177.63% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -6.00 | |||
ROE last 12 Months | 20.18 | |||
ROA (5Y Avg) | -1.16 | |||
ROA last 12 Months | 11.80 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | 14.79 | |||
Return on invested Capital Q | 7.89 | |||
Return on invested Capital Y | -5.81 | |||
Assets Turnover | 0.70 | |||
Receivables Turnover | 4.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
32.80 | ||||
5.23 | ||||
4.89 | ||||
17.80 | ||||
20.50 | ||||
2.72 | ||||
13.18 | ||||
9.27 | ||||
3.26B | ||||
Forward PE | 14.48 | |||
PEG | -3.58 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.90 | ||||
2.10 | ||||
0.21 | ||||
0.29 | ||||
27.40 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
59.00 | ||||
21.00 | ||||
27.00 | ||||
-0.10 | ||||
21.92 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
671.90M | ||||
9.76 | ||||
9.03 | ||||
6.28 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | 0.75 | 0.90 | 20.00 |
Q02 2022 | 0.64 | 0.81 | 26.56 |
Q01 2022 | 0.41 | 0.97 | 136.59 |
Q04 2021 | 0.17 | 0.25 | 47.06 |
Q03 2021 | 0.06 | 0.08 | 33.33 |
Q02 2021 | 0.05 | 0.11 | 120.00 |
Q01 2021 | -0.01 | 0.05 | 600.00 |
Q04 2020 | 0.03 | 0.07 | 133.33 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 QR | 0.87 | 8.75 | Positive |
12/2022 FY | 3.52 | 6.99 | Positive |
3/2023 QR | 0.95 | 9.20 | Positive |
12/2023 FY | 3.88 | 3.47 | Positive |
Next Report Date | 23rd Feb 2023 |
Estimated EPS Next Report | 0.87 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 817.34K |
Shares Outstanding | 68.83K |
Shares Float | 57.11M |
Trades Count | 13.84K |
Dollar Volume | 49.24M |
Avg. Volume | 939.91K |
Avg. Weekly Volume | 797.00K |
Avg. Monthly Volume | 898.94K |
Avg. Quarterly Volume | 1.12M |
Lantheus Holdings Inc. (NASDAQ: LNTH) stock closed at 60.8 per share at the end of the most recent trading day (a 0.23% change compared to the prior day closing price) with a volume of 817.34K shares and market capitalization of 4.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 595 people. Lantheus Holdings Inc. CEO is Mary Anne Heino.
The one-year performance of Lantheus Holdings Inc. stock is 132.24%, while year-to-date (YTD) performance is 19.31%. LNTH stock has a five-year performance of 177.63%. Its 52-week range is between 25.485 and 87.47, which gives LNTH stock a 52-week price range ratio of 56.97%
Lantheus Holdings Inc. currently has a PE ratio of 32.80, a price-to-book (PB) ratio of 5.23, a price-to-sale (PS) ratio of 4.89, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of 11.80%, a ROC of 14.79% and a ROE of 20.18%. The company’s profit margin is 21.92%, its EBITDA margin is 27.00%, and its revenue ttm is $671.89 Million , which makes it $9.76 revenue per share.
Of the last four earnings reports from Lantheus Holdings Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.87 for the next earnings report. Lantheus Holdings Inc.’s next earnings report date is 23rd Feb 2023.
The consensus rating of Wall Street analysts for Lantheus Holdings Inc. is Strong Buy (1), with a target price of $100.4, which is +65.13% compared to the current price. The earnings rating for Lantheus Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Lantheus Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Lantheus Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.34, ATR14 : 1.85, CCI20 : 157.25, Chaikin Money Flow : 0.28, MACD : 1.69, Money Flow Index : 84.57, ROC : 9.85, RSI : 73.59, STOCH (14,3) : 98.51, STOCH RSI : 1.00, UO : 76.10, Williams %R : -1.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Lantheus Holdings Inc. in the last 12-months were: Andrea Sabens (Sold 7 041 shares of value $405 210 ), Brian A. Markison (Option Excercise at a value of $483 320), Brian A. Markison (Sold 43 505 shares of value $3 655 192 ), Carol Walker (Sold 18 129 shares of value $1 003 783 ), Daniel M. Niedzwiecki (Sold 9 142 shares of value $607 993 ), Etienne Montagut (Sold 23 265 shares of value $1 396 427 ), Julie H. McHugh (Sold 7 280 shares of value $509 913 ), Mary Anne Heino (Sold 45 930 shares of value $2 709 378 ), Paul Blanchfield (Sold 6 142 shares of value $312 710 ), Paul M. Blanchfield (Sold 20 786 shares of value $1 162 297 ), Robert J. Marshall (Sold 31 778 shares of value $2 054 859 ), Samuel R. Leno (Option Excercise at a value of $102 482)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.
CEO: Mary Anne Heino
Telephone: +1 978 671-8001
Address: 331 Treble Cove Road, North Billerica 01862, MA, US
Number of employees: 595
Mon, 12 Dec 2022 06:00 GMT Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Better Therapeutics, Inc. (BTTX)
- TipRanks. All rights reserved.Wed, 07 Dec 2022 04:40 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Lantheus (LNTH) and Mayne Pharma Group Limited (OtherMAYNF)
- TipRanks. All rights reserved.Wed, 16 Nov 2022 08:02 GMT Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH), Chinook Therapeutics (KDNY) and Axsome Therapeutics (AXSM)
- TipRanks. All rights reserved.Mon, 14 Nov 2022 18:40 GMT Analysts Top Healthcare Picks: Lantheus (LNTH), Gamida Cell (GMDA)
- TipRanks. All rights reserved.Fri, 04 Nov 2022 12:25 GMT Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Lantheus (LNTH) and Deciphera Pharmaceuticals (DCPH)
- TipRanks. All rights reserved.Thu, 25 Aug 2022 06:45 GMT Lantheus (LNTH) Receives a Buy from B.Riley Financial
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.